nach oben

European Child & Adolescent Psychiatry

Erschienen in:

19.02.2018 | Original Contribution

Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis

verfasst von: Sarah C. O. S. Padilha, Suzane Virtuoso, Fernanda S. Tonin, Helena H. L. Borba, Roberto Pontarolo

Erschienen in: European Child & Adolescent Psychiatry | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to gather evidence of head-to-head double-blind randomized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder (ADHD) in children and adolescents. A systematic review was conducted by two independent reviewers in ten electronic databases (PROSPERO register CRD42016043239). Methodological quality of included studies was evaluated according to the Jadad scale. Network meta-analyses were performed including double-blinded head-to-head trials comparing active allopathic drugs in patients (0–18 years old) diagnosed with ADHD. The results of efficacy and safety of atomoxetine (ATX), bupropion, buspirone (BSP), dexamphetamine, edivoxetine (EDX), guanfacine (GXR), lisdexamfetamine (LDX), methylphenidate (MPH), mixed amphetamine salts, modafinil, pindolol (PDL), reboxetine (RBX), selegiline, and venlafaxine were analyzed using ADDIS software v.1.16.5. Forty-eight trials were identified (n = 4169 participants), of which 12 were used for efficacy analysis and 33 for safety analysis. On the CGI-I scale, the analysis revealed that MPH was more effective than ATX and GXR. For the safety outcomes, according to drug ranks, LDX was more likely to cause sleep disorders (39%) as well as loss of appetite (65%) and behavior problems such as irritability (60%). BSP (71%) and EDX (44%) caused less appetite decrease. For behavioral effects, PDL was considered safest (50%). For any adverse events, RBX (89%) was the safest alternative. The lack of head-to-head trials properly reporting outcomes of interest limited some comparisons. Network meta-analysis offered a broader overview on the available treatments for ADHD, especially for safety issues, and contributes towards evidence gathering and clinical practice decisions. A core outcome set for ADHD should be designed to guide the conduction and report of clinical trials.

Nur mit Berechtigung zugänglich

Polanczyk GV et al (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–442CrossRef

Austerman J (2015) ADHD and behavioral disorders: assessment, management, and an update from DSM-5. Cleve Clin J Med 82(11 Suppl 1):S2–S7CrossRef

Bruxel EM et al (2014) ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet B Neuropsychiatr Genet 165B(4):263–282CrossRef

Mohammadi MR, Mohammadzadeh S, Akhondzadeh S (2015) Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial. Iran J Psychiatry 10(2):106–114PubMedPubMedCentral

Root RW II, Resnick RJ (2003) An update on the diagnosis and treatment of attention-deficit/hyperactivity disorder in children. Prof Psychol Res Pract 34(1):34CrossRef

Lopresti AL (2015) Oxidative and nitrosative stress in ADHD: possible causes and the potential of antioxidant-targeted therapies. Atten Defic Hyperact Disord 7(4):237–247CrossRef

Stevens JR, Wilens TE, Stern TA (2013) Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord 15(2). https://doi.org/10.4088/PCC.12f01472

Stahl SM (2010) Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry 71(1):12–13CrossRef

Spiller HA, Hays HL, Aleguas A Jr (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 27(7):531–543CrossRef

10.

Nakanishi Y et al (2017) Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy. Child Adolesc Psychiatry Ment Health 11:26CrossRef

11.

Storebo OJ, et al (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev (11):Cd009885

12.

Rostain A et al (2015) Toward quality care in ADHD: defining the goals of treatment. J Atten Disord 19(2):99–117CrossRef

13.

Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ (2015) Clinical handbook of psychotropic drugs. Hogrefe Publishing Corporation/Hogrefe Publishing GmbH, Boston/GöttingenCrossRef

14.

Banaschewski T et al (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(Suppl 1):I102–I116PubMed

15.

Hennissen L et al (2017) Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 31:1–17CrossRef

16.

Jafarinia M et al (2012) Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol 27(4):411–418CrossRef

17.

Akhondzadeh S et al (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27(5):841–845CrossRef

18.

Arabgol F, Panaghi L, Hebrani P (2009) Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 18(1):53–59CrossRef

19.

Mohammadi MR et al (2010) Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Hum Psychopharmacol 25(7–8):560–565PubMed

20.

Zarinara AR et al (2010) Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol 25(7–8):530–535PubMed

21.

Song F et al (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338:b1147CrossRef

22.

Song F et al (2011) Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 343:d4909CrossRef

23.

Tonin FS et al (2015) Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: a network meta-analysis. Schizophr Res 169(1):483–485CrossRef

24.

Tonin FS et al (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract 1(1):943CrossRef

25.

Cortese S et al (2017) Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. BMJ Open 7(1):e013967CrossRef

26.

Punja S et al (2016) To meta-analyze or not to meta-analyze? A combined meta-analysis of N-of-1 trial data with RCT data on amphetamines and methylphenidate for pediatric ADHD. J Clin Epidemiol 76:76–81CrossRef

27.

Camporeale A et al (2015) Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. J Psychopharmacol 29(1):3–14CrossRef

28.

Chan E, Fogler JM, Hammerness PG (2016) Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA J Am Med Assoc 315(18):1997–2008CrossRef

29.

Cohen SC et al (2015) Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 54(9):728–736CrossRef

30.

Maneeton B et al (2015) Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. Drug Des Dev Ther 9:1927–1936CrossRef

31.

Maneeton N et al (2015) A systematic review of dexmethylphenidate versus placebo in child and adolescent ADHD: a meta-analysis of randomized, controlled trials. Eur Neuropsychopharmacol 25:S642CrossRef

32.

Joseph A et al (2017) Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry 26:1–23CrossRef

33.

Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane

34.

Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784CrossRef

35.

Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012CrossRef

36.

Jadad AR et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRef

37.

Jansen JP et al (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4):417–428CrossRef

38.

Dias S et al (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak 33(5):641–656CrossRef

39.

Weiss G et al (1971) Comparison of the effects of chlorpromazine, dextroamphetamine and methylphenidate on the behaviour and intellectual functioning of hyperactive children. Can Med Assoc J 104(1):20–25PubMedPubMedCentral

40.

Arnold LE et al (1972) Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch Gen Psychiatry 27(6):816–822CrossRef

41.

Huestis RD, Arnold LE, Smeltzer DJ (1975) Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double-blind comparison. Am J Psychiatry 132(8):868–870CrossRef

42.

Garfinkel BD, Webster CD, Sloman L (1975) Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction. Am J Psychiatry 132(7):723–728CrossRef

43.

Arnold LE et al (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry 35(4):463–473CrossRef

44.

Arnold LE et al (1976) Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch Gen Psychiatry 33(3):292–301CrossRef

45.

Conners CK, Taylor E (1980) Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry 37(8):922–930CrossRef

46.

Butter HJ et al (1983) A comparative study of the efficacy of ACTH4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesis. J Clin Psychopharmacol 3(4):226–230CrossRef

47.

Garfinkel BD et al (1983) Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 22(4):343–348CrossRef

48.

Donnelly M et al (1989) Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. Arch Gen Psychiatry 46(3):205–212CrossRef

49.

Zametkin A et al (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 42(10):962–966CrossRef

50.

Pelham WE Jr et al (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86(2):226–237PubMed

51.

Elia J et al (1993) Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry 34(5):785–804CrossRef

52.

Barrickman LL et al (1995) Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34(5):649–657CrossRef

53.

Buitelaar JK et al (1996) Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiatry 37(5):587–595CrossRef

54.

Efron D, Jarman F, Barker M (1997) Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100(6):E6CrossRef

55.

Pelham WE et al (1999) A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103(4):e43CrossRef

56.

Pelham WE et al (1999) A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 104(6):1300–1311CrossRef

57.

Pliszka SR et al (2000) A double-blind, placebo-controlled study of adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39(5):619–626CrossRef

58.

James RS et al (2001) Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 40(11):1268–1276CrossRef

59.

Overtoom CC et al (2003) Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res 145(1–2):7–15CrossRef

60.

Mohammadi MR et al (2004) Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 14(3):418–425CrossRef

61.

Mohammadi MR et al (2004) Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. J Clin Pharm Ther 29(2):139–144CrossRef

62.

Wigal S et al (2004) A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43(11):1406–1414CrossRef

63.

Wigal SB et al (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9(1):275–289CrossRef

64.

Sangal RB et al (2006) Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 29(12):1573–1585CrossRef

65.

Biederman J et al (2007) Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62(9):970–976CrossRef

66.

Wang Y et al (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 41(3):222–230CrossRef

67.

Amiri S et al (2008) Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32(1):145–149CrossRef

68.

Newcorn JH et al (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165(6):721–730CrossRef

69.

Daviss WB et al (2008) Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 47(2):189–198CrossRef

70.

Palumbo DR et al (2008) Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 47(2):180–188CrossRef

71.

Nair V, Mahadevan S (2009) Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. J Trop Pediatr 55(2):116–121CrossRef

72.

Davari-Ashtiani R et al (2010) Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial. Child Psychiatry Hum Dev 41(6):641–648CrossRef

73.

Stein MA et al (2011) Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol 21(6):581–588CrossRef

74.

Mohammadi MR et al (2012) Buspirone versus methylphenidate in the treatment of children with attention- deficit/hyperactivity disorder: randomized double-blind study. Acta Med Iran 50(11):723–728PubMed

75.

Coghill D et al (2013) European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23(10):1208–1218CrossRef

76.

Santisteban JA et al (2014) Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder. CNS Drugs 28(9):825–833CrossRef

77.

Lin DY et al (2014) A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 24(4):190–200CrossRef

78.

Dittmann RW et al (2013) Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 27(12):1081–1092CrossRef

79.

Nagy P et al (2016) Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry 25(2):141–149CrossRef

80.

Arabgol F, Panaghi L, Nikzad V (2015) Risperidone versus methylphenidate in treatment of preschool children with attention-deficit hyperactivity disorder. Iran J Pediatr 25(1):e265CrossRef

81.

McCracken JT et al (2016) Combined stimulant and guanfacine administration in attention-deficit/hyperactivity disorder: a controlled, comparative study. J Am Acad Child Adolesc Psychiatry 55(8):657.e1–666.e1CrossRef

82.

Huss M et al (2015) Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, double-blind, multicentre, placebo- and active-reference phase 3 study. Aust N Z J Psychiatry 49:111

83.

Efron D, Jarman F, Barker M (1997) Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100(4):662–666CrossRef

84.

ATTENTION-DEFICIT SO (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011–2654

85.

Rezaei G et al (2016) Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review and meta-analysis. Med J Islam Repub Iran 30:325PubMedPubMedCentral

86.

Thapar A, Cooper M (2016) Attention deficit hyperactivity disorder. Lancet 387(10024):1240–1250CrossRef

87.

Chierrito de Oliveira D, et al (2017) Safety of treatments for ADHD in adults: pairwise and network meta-analyses. J Atten Disord. https://doi.org/10.1177/1087054717696773 CrossRefPubMed

88.

Apter JT, Allen LA (1999) Buspirone: future directions. J Clin Psychopharmacol 19(1):86–93CrossRef

89.

Coghill DR et al (2014) Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry 23(2):61–68CrossRef

90.

Cohen-Yavin I et al (2009) Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Clin Neuropharmacol 32(4):179–182CrossRef

91.

Page ME (2003) The promises and pitfalls of reboxetine. CNS Drug Rev 9(4):327–342CrossRef

92.

Eyding D et al (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737CrossRef

93.

Preskorn SH (2004) Reboxetine: a norepinephrine selective reuptake pump inhibitor. J Psychiatr Pract 10(1):57–63CrossRef

94.

Sepede G et al (2012) Reboxetine in clinical practice: a review. Clin Ter 163(4):e255–e262PubMed

95.

Ghanizadeh A (2015) A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry 69(4):241–248CrossRef

96.

Kirkham JJ et al (2013) Can a core outcome set improve the quality of systematic reviews?–a survey of the Co-ordinating Editors of Cochrane Review Groups. Trials 14:21CrossRef

Titel: Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis
verfasst von: Sarah C. O. S. Padilha
Suzane Virtuoso
Fernanda S. Tonin
Helena H. L. Borba
Roberto Pontarolo
Publikationsdatum: 19.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Child & Adolescent Psychiatry / Ausgabe 10/2018
Print ISSN: 1018-8827
Elektronische ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-018-1125-0

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Using the Dutch multi-informant Strengths and Difficulties Questionnaire (SDQ) to predict adolescent psychiatric diagnoses

A cost-effectiveness analysis of school-based suicide prevention programmes

Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case–control study

Adult outcomes of conduct problems in childhood or adolescence: further evidence of the societal burden of conduct problems